^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral replication inhibitor

    Related drugs:
    1d
    A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers (clinicaltrials.gov)
    P1, N=66, Completed, Traws Pharma, Inc. | Recruiting --> Completed | N=32 --> 66
    Trial completion • Enrollment change
    7d
    Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Aligos Therapeutics
    New P1 trial
    7d
    Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Aligos Therapeutics
    New P1 trial
    10d
    PULSE-US: A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe (clinicaltrials.gov)
    P=N/A, N=131005, Completed, Pfizer | N=84584 --> 131005
    Enrollment change • HEOR
    27d
    A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants (clinicaltrials.gov)
    P1, N=0, Withdrawn, Pfizer | N=28 --> 0 | Trial completion date: Jun 2025 --> Dec 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2025 --> Dec 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    1m
    ZELA: Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) (clinicaltrials.gov)
    P2/3, N=366, Recruiting, Airway Therapeutics, Inc. | Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Mar 2028
    Enrollment open • Trial primary completion date
    1m
    TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2 (clinicaltrials.gov)
    P=N/A, N=1178, Completed, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting --> Completed | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    1m
    Study Investigating the Safety and Immunogenicity of AB-729 and VTP 300 in Virologically Suppressed CHB Participants (ACTRN12622000317796)
    P2, N=62, Completed, Arbutus Biopharma | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab)
    1m
    A Study of RBD1016 in CHB Participants (clinicaltrials.gov)
    P2, N=48, Completed, Suzhou Ribo Life Science Co. Ltd. | Active, not recruiting --> Completed
    Trial completion
    2ms
    PRIOH-1: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (clinicaltrials.gov)
    P3, N=158, Completed, AiCuris Anti-infective Cures AG | Active, not recruiting --> Completed
    Trial completion
    |
    Zyclara (imiquimod)
    2ms
    A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions. (clinicaltrials.gov)
    P=N/A, N=99000, Active, not recruiting, Pfizer
    New trial • Real-world evidence
    2ms
    A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19. (clinicaltrials.gov)
    P=N/A, N=8252912, Completed, Pfizer | Recruiting --> Completed | Trial completion date: Dec 2025 --> Feb 2025 | Trial primary completion date: Dec 2025 --> Feb 2025
    Trial completion • Trial completion date • Trial primary completion date • HEOR • Real-world evidence